article thumbnail

STAT+: Cancer therapy’s new ‘gold rush’:  bispecific antibodies that hit key combination of targets

STAT

” Experts told STAT there’s been a surge of interest for these compounds from biotech and pharma in the last few months, spurred on most by the presentation of promising clinical data from Summit Therapeutics.

Immunity 361
article thumbnail

Cancer therapeutics present strongest innovation pipeline in next five years, says GlobalData

Express Pharma

In a recent GlobalDatas survey, The State of the Biopharmaceutical Industry 2025, the largest proportion (41 per cent) of surveyed pharmaceutical industry professionals indicated that the immuno-oncology/ cancer therapeutics present the strongest innovation pipeline in the next five years.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Opinion: I helped declare the U.S. measles-free in 2000. I’m dismayed by where we are now

STAT

I neglected to have my first child vaccinated against chickenpox; the scars are still present. I offered vaccines to my patients and was adherent to the routine schedules, but certainly did not go out of my way to encourage or cajole. Twenty-five years ago this week, however, I attended the 2000 CDC Measles Elimination Meeting in Atlanta.

Vaccines 291
article thumbnail

STAT+: How Pfizer used wearables to tap into the promise of an experimental drug

STAT

While the weight gain was significant, experts at the time said the study’s secondary endpoints, including patient-reported outcomes and physical activity measured by a wearable, presented a more nuanced portrait of how the treatment was influencing patients.

346
346
article thumbnail

STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present

STAT

For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place where researchers have developed new therapies in-house and published high-impact papers.

357
357
article thumbnail

Opinion: Diagnostic tests for rare conditions present a mathematical conundrum

STAT

Worried about your health? You can now avail yourself of noninvasive diagnostics that claim to screen for rare birth defects, cancer-associated mutations, and even Alzheimer’s.

Labelling 338
article thumbnail

STAT+: Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug

STAT

But in a clinical trial presented last year , 14 out of 50 patients with relapsed disease saw their tumors shrink. It responds poorly to chemotherapy and is usually driven by a mutation that can’t be drugged with traditional approaches. Median survival is generally cited as less than a year.